Compare Allegion PLC (ALLE) vs Cassava Sciences Inc (FLNA) Price & Performance

ALLE trades at $165.9, up 0.22% today, near its consensus price target of $156. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates, driven by 13% revenue growth and margin expansion in the Americas segment. Recent news highlights raised full-year guidance and institutional buying interest.

Outlook remains positive given earnings momentum and raised guidance, but risks include reliance on Americas growth and cost pressures. Analyst sentiment is mixed with a Hold consensus, yet the stock's current price above the target suggests limited near-term upside. Execution on international growth and margin sustainability are key for further appreciation.

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.